EGFR and lung adenocarcinoma: Second, among the 703 patients with pathological stage IB-IIIA primary lung adenocarcinoma during the analysis period, 8.3% and 8.5% of the patients did not undergo EGFR mutation analysis and PET-CT, respectively.